The Defense Logistics Agency - Troop Support is seeking sources capable of providing Skin Decontamination Lotion, NSN 6505-01-507-5074. Shall be a topical lotion containing a free oxime dissolved in a mixture of polyethylene glycol monomethyl ether and water. The lotion is intended to remove or neutralize chemical warfare agent and T-2 toxin from the skin. Shall reduce toxic effects of warfare agents; HD, Soman (GD), and VX on skin. Shall be pre-impregnated in a suitable sponge applicator pad. Each applicator pad shall be individually packaged in a heat-sealed polyethylene-lined aluminum foil pouch. The foil pouch shall permit easy opening of the package when wearing CW protective clothing. Shall be cleared for use by the U.S. Food and Drug Administration (FDA) for application on unbroken skin of hands, face, neck, limbs, and torso. The manufacturer shall also provide a training lotion that imitates the properties of the decontamination lotion in all but active decontaminating ingredients.

DLA Troop Support has annual requirements between 720,000 and 1,260,000 packets of lotion estimated for the next 5 years. Ordered quantities shall be delivered to military ordering activities or Defense depots located throughout the United States. Delivery should occur 60 days after receipt of order. The Government will guarantee a minimum purchase of 252,000 packets per year.

This is a request for information (RFI) and does not commit the U.S. Government to issue a solicitation, make an award, or pay any costs associated with responding to this announcement. All submitted information shall remain with the U.S. Government and will not be returned.

***CURRENTLY MARKETED DECONTAMINATING LOTION***

If your firm currently markets decontaminating lotion, please provide information with respect to the following:

a) Place of manufacture
b) Estimated annual capacity
c) FDA registration
d) Product name and description including description of any special features
e) Current unit sale price
f) Estimated inventory level and storage requirements

*** NEW PRODUCTS UNDER DEVELOPMENT***

For products under development, describe the current stage of development and whether the product has undergone independent laboratory testing or FDA testing/trials etc.
Firms and organizations that currently develop or manufacture lotions described in this RFI or that have technologies, pharmaceuticals, or manufacturing capabilities under development are invited to submit information to DLA Troop Support. Data obtained from this RFI will be used by DLA Troop Support in making recommendations and decisions on the development of an appropriate planning and procurement strategy for adenovirus vaccine. All information submitted will be kept confidential as allowed by relevant Federal law and will be eligible for additional special protections under the conditions of the Protected Critical Infrastructure Information (PCII) Program outlined in the Critical Infrastructure Information Act of 2002.

Your response to this RFI may be submitted electronically in pdf format and emailed to [email protected]